GlassScriptPhysician profile
Melissa N Walsh
NPI 1033512918
$2,355.52
in general payments reported to CMS, 2019-2025
37 companies · $738 in 2025
The $738 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $159 · 2023: $1,101 · 2024: $357 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.47 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $238.86 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $196.27 | 2023-2025 | |
| Seagen INC. | $182.15 | 2023-2025 | Tukysa, Tivdak, Padcev |
| Abbvie INC. | $161.32 | 2023-2025 | |
| Janssen Biotech, INC. | $150.47 | 2023-2025 | Carvykti, Rybrevant, Darzalex |
| Janssen Scientific Affairs, LLC | $139.80 | 2025 | Darzalex, Carvykti, Tecvayli |
| Kite Pharma, INC. | $121.20 | 2022 | |
| Amgen INC. | $115.37 | 2023 | Kyprolis, Xgeva, Vectibix |
| Glaxosmithkline, LLC. | $112.53 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Genentech, INC. | $93.61 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $78.79 | 2022-2024 | |
| Celgene Corporation | $55.19 | 2023 | Reblozyl |
| Eisai INC. | $54.10 | 2025 | |
| Genmab U.S., INC. | $51.27 | 2023-2025 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $50.03 | 2023-2024 | Opdivo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.